Zacks Investment Research
06 Aug 2026, 14:51 UTC · 13w ago
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates
Impact · against what's priced in
CG Oncology's Q2 results show a significant revenue miss and a widening loss, continuing a trend of missing earnings estimates. The results indicate operational headwinds and inefficient burn rates that likely outweigh recent price momentum.
- CGON−0.60
No priced-in read yet
- In context
The company missed revenue estimates by 59.02% ($1.16 million actual) and reported a larger than expected loss of $0.90 per share, continuing a pattern of missing EPS estimates in three of the last four quarters.
Read from the article alone
Top 1 mover · tap to explore
